Does brigatinib have an obvious effect on brain metastasis?

Brigatinib (Brigatinib), as a targeted therapy drug for non-small cell lung cancer (NSCLC), has shown significant efficacy especially in patients with positive ALK fusion genes.

From the perspective of drug mechanism, brigatinib has good blood-brain barrier penetration. This feature enables it to reach and act on the lesion site more effectively when treating brain metastases from lung cancer. Brigatinib is therefore able to achieve better results in controlling brain metastases than traditional chemotherapy drugs.

Clinical trial data also provide strong support for the efficacy of brigatinib in the treatment of brain metastases. For example, ALTA-1LThis international multi-center, randomized controlled phase III study showed that compared with the first-generation ALK inhibitor crizotinib, brigatinib can significantly reduce the risk of intracranial progression or death in patients with lung cancer with brain metastases. Specifically, patients in the brigatinib group experienced a 69% reduction in their risk of intracranial progression or death for at least 2 years. At the same time, the study also found that brigatinib also performed well in prolonging the progression-free survival (PFS) of patients, with the median PFS being extended by more than 2 times during 2 years of follow-up.

Actual case reports have also verified the therapeutic effect of brigatinib on brain metastases. Case reports show that after receiving brigatinib treatment, patients’ brain metastases were effectively controlled and their quality of life was significantly improved. The therapeutic effects of these actual cases further confirm the application value of brigatinib in clinical practice.

It is worth noting that although brigatinib has shown significant results in the treatment of brain metastases, it is not suitable for all patients with lung cancer. Its efficacy is mainly limited to patients who are positive for the ALK fusion gene. In addition, the use of brigatinib may also be associated with certain side effects, such as gastrointestinal problems such as nausea, vomiting, and diarrhea, as well as central nervous system symptoms such as fatigue and drowsiness. Therefore, when using brigatinib, individualized assessment and treatment plans need to be formulated based on the patient's specific situation.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10883856